Cargando...
Overview of Humira(®) biosimilars: current European landscape and future implications
Humira(®) (adalimumab) by AbbVie has been the top-selling biologic drug product for the last few years – reaching nearly $20 billion in annual sales in 2018. Upon the October 2018 release of four adalimumab biosimilars into the European market, those sales began to shrink. By the end of 2019, the an...
Guardado en:
| Publicado en: | J Pharm Sci |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8014989/ https://ncbi.nlm.nih.gov/pubmed/33556387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.xphs.2021.02.003 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|